A CONSORT-Compliant, Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Purified Anthocyanin in Patients with Nonalcoholic Fatty Liver Disease

Medicine (United States)

Volumn 94, Issue 20, 2015, Pages

  Zhang, Pei Wen ^a,b   Chen, Feng Xia ^a   Li, Di ^b   Ling, Wen Hua ^b   Guo, Hong Hui ^a  

^a SHAOGUAN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTHOCYANIN; BIOLOGICAL MARKER; CYTOKERATIN 18; GLUCOSE; LIPID; MYELOPEROXIDASE; PLACEBO; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRIC PARAMETERS; ARTICLE; BILBERRY; BLACK CURRANT; CONTROLLED STUDY; DIET; DIET RESTRICTION; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; DRUG PURIFICATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; NUTRIENT; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL ACTIVITY; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTATION; TREATMENT DURATION; BLOOD; GLUCOSE TOLERANCE TEST; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE;

ADULT; ANTHOCYANINS; CHOLESTEROL; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PILOT PROJECTS; TRIGLYCERIDES;

EID: 84937965378     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000758     Document Type: Article

References (40)

1. Bhala N, Angulo P, van der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology. 2011;54:1208-1216.
2. Fierbinteanu-Braticevici C, Negreanu L, Tarantino G. Is fatty liver always benign and should not consequently be treated? J Physiol Pharmacol. 2013;64:3-9.
3. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865-873.
4. Hui AY, Wong VW, Chan HL, et al. Histological progression of non-alcoholic fatty liver disease in Chinese patients. Aliment Pharmacol Ther. 2005;21:407-413.
5. Wong VW, Chan HL, Hui AY, et al. Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese. Aliment Pharmacol Ther. 2004;20:45-49.
6. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-1685.
7. Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145:574-582.
8. Stein LL, Dong MH, Loomba R. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: current status. Adv Ther. 2009;26:893-907.
9. Finelli C, Tarantino G. Is there any consensus as to what diet or lifestyle approach is the right one for NAFLD patients? J Gastrointestin Liver Dis. 2012;21:293-302.
10. McCarthy EM, Rinella ME. The role of diet and nutrient composition in nonalcoholic fatty liver disease. J Acad Nutr Diet. 2012;112:401-409.
11. Wedick NM, Pan A, Cassidy A, et al. Dietary flavonoid intakes and risk of type 2 diabetes in US men and women. Am J Clin Nutr. 2012;95:925-933.
12. Mink PJ, Scrafford CG, Barraj LM, et al. Flavonoid intake and cardiovascular disease mortality: a prospective study in postmenopausal women. Am J Clin Nutr. 2007;85:895-909.
13. Cassidy A, Mukamal KJ, Liu L, et al. High anthocyanin intake is associated with a reduced risk of myocardial infarction in young and middle-aged women. Circulation. 2013;127:188-196.
14. Jennings A, Welch AA, Spector T, et al. Intakes of anthocyanins and flavones are associated with biomarkers of insulin resistance and inflammation in women. J Nutr. 2014;144:202-208.
15. Tang X, Shen T, Jiang X, et al. Purified anthocyanins from bilberry and black currant attenuate hepatic mitochondrial dysfunction and steatohepatitis in mice with methionine and choline deficiency. J Agric Food Chem. 2015;63:552-561.
16. Morrison MC, Liang W, Mulder P, et al. Mirtoselect, an anthocyanin-rich bilberry extract, attenuates non-alcoholic steatohepatitis and associated fibrosis in ApoE-3Leiden mice. J Hepatol. 2015;62:1180-1186.
17. Guo H, Xia M, Zou T, et al. Cyanidin 3-glucoside attenuates obesity-associated insulin resistance and hepatic steatosis in high-fat diet-fed and db/db mice via the transcription factor FoxO1. J Nutr Biochem. 2012;23:349-360.
18. Suda I, Ishikawa F, Hatakeyama M, et al. Intake of purple sweet potato beverage affects on serum hepatic biomarker levels of healthy adult men with borderline hepatitis. Eur J Clin Nutr. 2008;62:60-67.
19. Guo H, Zhong R, Liu Y, et al. Effects of bayberry juice on inflammatory and apoptotic markers in young adults with features of non-alcoholic fatty liver disease. Nutrition. 2014;30:198-203.
20. Younossi ZM, Stepanova M, Negro F, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore). 2012;91:319-327.
21. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.
22. Qin Y, Xia M, Ma J, et al. Anthocyanin supplementation improves serum LDL-and HDL-cholesterol concentrations associated with the inhibition of cholesteryl ester transfer protein in dyslipidemic subjects. Am J Clin Nutr. 2009;90:485-492.
23. Zhu Y, Ling W, Guo H, et al. Anti-inflammatory effect of purified dietary anthocyanin in adults with hypercholesterolemia: a randomized controlled trial. Nutr Metab Cardiovasc Dis. 2013;23:843-849.
24. Lee IT, Chan YC, Lin CW, et al. Effect of cranberry extracts on lipid profiles in subjects with type 2 diabetes. Diabet Med. 2008;25:1473-1477.
25. Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. J Am Med Assoc. 2013;310:948-959.
26. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846-854.
27. Little RJ, D'Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367:1355-1360.
28. Fitzpatrick E, Mitry RR, Quaglia A, et al. Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. J Pediatr Gastroenterol Nutr. 2010;51:500-506.
29. Schindhelm RK, van der Zwan LP, Teerlink T, et al. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification? Clin Chem. 2009;55:1462-1470.
30. Stull AJ, Cash KC, Johnson WD, et al. Bioactives in blueberries improve insulin sensitivity in obese, insulin-resistant men and women. J Nutr. 2010;140:1764-1768.
31. Wright OR, Netzel GA, Sakzewski AR. A randomized, double-blind, placebo-controlled trial of the effect of dried purple carrot on body mass, lipids, blood pressure, body composition, and inflammatory markers in overweight and obese adults: the QUENCH trial. Can J Physiol Pharmacol. 2013;91:480-488.
32. Hassellund SS, Flaa A, Kjeldsen SE, et al. Effects of anthocyanins on cardiovascular risk factors and inflammation in pre-hypertensive men: a double-blind randomized placebo-controlled crossover study. J Hum Hypertens. 2013;27:100-106.
33. Joka D, Wahl K, Moeller S, et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology. 2012;55:455-464.
34. Kwok R, Tse YK, Wong GL, et al. Systematic review with metaanalysis: non-invasive assessment of non-alcoholic fatty liver disease: the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014;39:254-269.
35. Jiang X, Tang X, Zhang P, et al. Cyanidin-3-O-beta-glucoside protects primary mouse hepatocytes against high glucose-induced apoptosis by modulating mitochondrial dysfunction and the PI3K/Akt pathway. Biochem Pharmacol. 2014;90:135-144.
36. Nussbaum C, Klinke A, Adam M, et al. Myeloperoxidase: a leukocyte-derived protagonist of inflammation and cardiovascular disease. Antioxid Redox Signal. 2013;18:692-713.
37. Rensen SS, Bieghs V, Xanthoulea S, et al. Neutrophil-derived myeloperoxidase aggravates non-alcoholic steatohepatitis in lowdensity lipoprotein receptor-deficient mice. PLoS One. 2012;7:e52411.
38. Gomez Garcia A, Rivera Rodriguez M, Gomez Alonso C, et al. Myeloperoxidase is associated with insulin resistance and inflammation in overweight subjects with first-degree relatives with type 2 diabetes mellitus. Diabetes Metab J. 2015;39:59-65.
39. Rensen SS, Slaats Y, Nijhuis J, et al. Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis. Am J Pathol. 2009;175:1473-1482.
40. Guo H, Ling W. The update of anthocyanins on obesity and type 2 diabetes: experimental evidence and clinical perspectives. Rev Endocr Metab Disord. 2015;16:1-13.